05.09.2014 • NewsCatalentinvestmentEli Lilly

Catalent Invests in Automated Packaging to Support Lilly

Catalent Pharma Solutions is installing new automated prefilled syringe clinical packaging lines at its Clinical Supply Center of Excellence in Philadelphia, Pennsylvania, USA, to support its strategic partner, US drugmaker Eli Lilly.

The US-based provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products already has installed automated prefilled syringe packaging capabilities in its clinical supply facility in Schorndorf, Germany.

The packaging line at Philadelphia is said to enable fully automated insertion of plunger rods, application of randomized and non-randomized labels and back-stop clips as well as off-line labeling with booklet labels.

Catalent said the investment reflects a "strong commitment" to jointly share growth strategies, risks with long-term strategic partners.

"Our continued investments in clinical packaging, cold chain storage, digital solutions, and our expansion into China are all part of our growth strategy and commitment to our customers to help them reduce clinical trial timelines," said Gerry Hepburn, Chief operating officer, vice president and general manager of Catalent's clinical supply services business.

 

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read